Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study

Table 2 Psychosis risk by medications (intrasubject comparison)

			Total		Age <70y		Age > = 70y
			Adjusted HR* (95% CI)	P Value	Adjusted HR* (95% CI)	P Value	Adjusted HR* (95% CI)	P Value
Drugs	L-Dopa	Per 100 mg /day	0.92(0.79-1.07)	0.27	1.06(0.85-1.32)	0.59	0.82(0.67-1.00)	0.05
	DA agonists	Per 100 mg(LDED) /day	1.25(0.88-1.77)	0.20	0.85(0.51-1.42)	0.53	1.65(1.02-2.66)	0.035
	Amantadine	Per 50 mg /day	0.87(0.75-1.02)	0.08	0.76(0.55-1.05)	0.09	0.86(0.63-1.17)	0.33
	Selegiline	Per 2.5 mg /day	1.06(0.85-1.33)	0.590	0.88(0.64-1.21)	0.42	1.24(0.76-2.01)	0.39
	Anti-cholinergics	Use	19.7(2.39-163)	0.006	0.80(0.38-1.68)	0.55	188.4(13.91-2551)	<0.0001
		Not use (Ref)	1		1		1
	Donepezil use	Use	0.48(0.27-0.85)	0.012	0.79(0.51-1.22)	0.29	0.28(0.08-1.01)	0.051
		Not use (Ref)	1		1		1
Interaction	Anti-cholinergics X duration	0.76	(0.64-0.89)	0.001			0.62(0.50-0.77)	<0.0001

Dopa were expressed as adjusted values including concomitant entacapone.
*HR was adjusted for age, sex, mH-Y (1-3 vs 4-5), MMSE (= < 24 vs >24) and duration of PD, using a generalized estimating equation.
HR was calculated for Dopa (100 mg/d, adjusted), DA agonist (LDED, 100 mg/d), selegiline (2.5 mg/d), amantadine (50 mg/d), anti-cholinergics (use vs not use), and donepezil (use vs not use).
Hazard period: prescription at psychosis occurrence.
Control period: prescription 1 month and 3 months before psychosis occurrence.

ISSN: 1471-2377